EU-ANTI-P-4E-BP1 (THR37/46)-Revvity
Order
Cat.NO Name Size
TRF0216-M EU-ANTI-P-4E-BP1 (THR37/46) 100 UG

 

  • Product overview
  • Brand introduction
  • Q&A
  • Data download

LANCE Ultra TR-FRET technology provides a two-component kinase assay that combines direct labeling of the kinase substrate with ULight™, an innovative emission dye for optimum binding efficiency, reducing steps and assay prep time. Validated for over 310 kinases, we provide data transparency by supplying:

 

  • Test conditions: Rapid assay setup to move straight into optimized assay performance
  • S:B data: Confidence in proven performance of the kinase on specific substrates; no guessing
  • Phospho-motifs: Substrate sequences are provided
  • Assay options: Multiple substrates are tested so you can select the best peptide sequence and S:B for your kinase

 

For this antibody

  • 10 μg = 1,562 assay points
  • 100 μg = 15,625 assay points

 

In LANCE Ultra kinase assays, the binding of a Eu-labeled anti-phosphosubstrate antibody to the phosphorylated ULight-labeled substrate brings donor and acceptor molecules into close proximity. After irradiation of the kinase reaction at 320 or 340 nm, the energy from the Eu donor is transferred to the ULight acceptor dye, which in turn generates light at 665 nm. The intensity of the light emission is proportional to the level of ULight-substrate phosphorylation.

Specifications

 

 

 

Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

 

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.

×